Abstract. This is a sub-study of a larger randomised controlled trial on HIV-infected Zambian 1 children, which revealed that cotrimoxazole prophylaxis reduced morbidity and mortality despite 2 a background of high cotrimoxazole resistance. The impact of cotrimoxazole on carriage and 3 antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae as major causes 4 of childhood mortality in HIV-infected children was investigated as these are unclear. 5
Introduction
To estimate the change in carriage over time mixed effect logistic regression models were used 1 that included the child as a random effect. Separate slopes and intercepts were included for 2 placebo and CoT treatment arms. No random effect for time was included as this resulted in 3 model instability. 4
Other factors were also included individually in the model to estimate any univariable effects on 5 carriage. These factors were: age of child at date of specimen, sex of child, CD4% within 7 days 6 either side of date of specimen, change in CD4% from baseline, and calendar month at which 7 specimen was taken.
2 test for independence was used to compare rates of resistance in post-8 baseline samples between treatment arms. Stata version 10.1 was used to perform these analyses. 9
Results 10 Baseline characteristics. There were 534 children randomized, of these 439 (225 on CoT arm 11 and 214 on placebo arm) had nasal swabs collected and were included in this study. One hundred 12 and eighty one children (92 CoT and 89 placebo recipients) had baseline swabs on or prior to 13 randomisation. Baseline characteristics are shown in Table 1 . Baseline specimens were collected 14 a median of 3 days (IQR 10 to 0 days) prior to randomisation. All baseline specimens were taken 15 prior to the initiation of study treatment. At baseline, 93 (51%) children carried S. pneumoniae, 16
Factors influencing nasopharyngeal carriage. Specimens from children who had received 18 antibiotics known to be active against S. pneumoniae or H. influenzae within the two weeks prior 19 to specimen collection were less likely to have carriage. Sixty one percent (104/170) of the nose 20 swabs from children who had received antibiotics known to be active against S. pneumoniae 21 within the two weeks prior to specimen collection did not have carriage of S. pneumoniae 22 on July 8, 2017 by guest http://aac.asm.org/ Downloaded from compared to 45% (536/1182) specimens from children who had not received such antibiotics 1 within the two weeks prior to specimen collection (p<0.001). 2
Eighty six percent (148/173) of the nose swabs from children who had received antibiotics 3 known to be active against H. influenzae within the two weeks prior to specimen collection did 4 not have carriage of H. influenzae compared to 72% (850/1179) specimens from children who 5
had not received such antibiotics within the two weeks prior to specimen collection (p<0.001). 6
Thus, the specimens from children who had received antibiotics known to be active against S. 7 pneumoniae or H. influenzae within the two weeks prior to specimen collection were excluded 8 from the analyses of carriage of S. pneumoniae or H. influenzae. There may be some under 9 reporting of antibiotic use, but we would expect this to be distributed approximately equally 10 between placebo and CoT groups as a result of randomisation. 11 S. pneumoniae. The level of carriage was similar in both arms of the trial (Figure 1 ). There was 12 no change in carriage of S. pneumoniae over time in the placebo arm, odds ratio 1.09 per 52 13 weeks, 95% CI (0.80, 1.48). However, there was an apparent increase in carriage in the CoT 14 arm, from 48% at baseline to 59% at week 96 (Figure 1) , odds ratio 1.63 per 52 weeks, 95% CI 15 (1.23, 2.16), p=0.001. None of CD4%, change in CD4% from baseline, age of child at date of 16 specimen, sex of child or calendar month in which specimen was taken were associated with the 17 carriage of S. pneumoniae (Table 2) .specimen or sex of child with the carriage of H. influenzae. Carriage was found to be less 1 frequent in the rainy season (December to February) compared to other seasons (Table 2) . 2
Longitudinal patterns of nasopharyngeal carriage. Tables 3a and 3b summarise the  3 longitudinal patterns of carriage of S. pneumoniae and H. influenzae, respectively during the trial 4 by looking at consecutive pairs of specimens taken from an individual child during the trial. 5
There was no statistical evidence for a difference in patterns of switching in carriage of S. 6 pneumoniae between placebo and CoT overall (p=0.18, Table 3a), but there was a suggestion that 7 the chance of remaining carriage free was higher in the placebo arm compared with the CoT arm 8 (p=0.10). Patterns of switching in carriage of H. influenzae (Table 3b ) differed between the CoT 9 and placebo arms (p=0.04) with higher rates of switching from carriage to no carriage observed 10 in the placebo arm (p=0.02). 11
The median time from randomisation to the last specimen was significantly greater in the CoT 12 arm (56 months) than in the placebo arm (48 months), p=0.001 using the Wilcoxon rank-sum test 13 of difference between randomised groups in time from randomisation to last specimen. 14 The number of pairs of specimens per person-year were similar in the placebo and CoT arms (p = 15 0.14), 2.74 and 2.54 respectively for the S. pneumoniae analysis (with very similar figures for theresults of resistance to CoT. Of the 140 on the CoT arm, 78 (56%) had resistance to CoT, but 1 only 50 (38%) of the 130 on the placebo arm had resistance to CoT (p=0.005). 2   Tables 4a and 4b summarise the longitudinal patterns of resistance to CoT of S. pneumoniae and 3 H. influenzae respectively during the trial by looking at consecutive pairs of specimens taken 4 from an individual child during the trial. Resistance to other antibiotics was considered too 5 infrequent for any formal analysis. Patterns of switching of resistance of S. pneumoniae to CoT 6 (Table 4a ) differed between the CoT and placebo arms (p=0.005) with 3-fold higher rate of loss 7 of CoT resistance in the placebo arm. There was no statistical evidence for a difference in 8 patterns of switching of resistance of H. influenzae to CoT (p=0.29, Table 4b ), but there was a 9
suggestion that the chance of remaining CoT sensitive was higher in the placebo arm. 10
The number of pairs of specimens per 100 person-years was similar in the placebo and CoT arms: 11 2.13 and 2.03 respectively for the resistance of S. pneumoniae analysis (p=0.46) and 1.89 and 12 1.88 respectively for the resistance of H. influenzae (p=0.99). 13
Discussion 14
To our knowledge this is the first study to measure the nasopharyngeal carriage and antibiotic 15 resistance of two important pathogens, S. pneumoniae and H. influenzae in HIV-infected children 16 on CoT prophylaxis versus placebo over two years. This study revealed that the pneumococcal 17 level of carriage is high (51% at baseline) in agreement with other studies undertaken in Africa. sensitive S. pneumoniae (p=0.002), and there was also a suggestion in H. influenzae that the 1 chance of remaining sensitive was lower in the CoT arm (p=0.05). These findings did not alter 2 the ability of CoT prophylaxis to reduce morbidity and mortality in HIV-infected children. There 3 were no associations observed between CD4 levels and the carriage of either S. pneumoniae or H. 4
influenzae. 5
Nasopharyngeal carriage. The pneumococcal carriage rates observed in this study were similar 6 to (9;29), or lower than other African studies (28;52). The higher carriage levels observed in the 7 latter two studies may be due to the younger median age of the children (1.7 years) compared to 8 this study, 5.1 (IQR 2.8,8.7) years at baseline. 9
A gradual rise in the pneumococcal carriage rate was observed in the CoT prophylaxis arm and a 10 similar trend was seen in the placebo arm, though not statistically significant. This may have 11 been due to an improvement in sampling efficiency over time. 12
Children on the CoT arm were more likely to maintain carriage of H. influenzae compared to 13 placebo (p = 0.02). There was also a suggestion that the chance of remaining free of carriage of 14 S. pneumoniae was higher in the placebo arm than the CoT arm (p=0.10). An increasing number 15 of new acquisitions, has been observed in healthy children as they get older and acquire 16 immunity to an increasing number of serotypes (23). Paradoxically, by 48 weeks the children in 17 the treatment arm have a slightly higher level of pneumococcal carriage compared with children 18 in the placebo arm. This maybe due to a difference in behaviour such that the healthier children 19 on cotrimoxazole prophylaxis are more likely to attend school or community centres and play 20 together and increase the level of transmission and therefore carriage. 21
on July 8, 2017 by guest http://aac.asm.org/ Downloaded from 1 influenzae were resistant to CoT. A study on paediatric population of children (that were not 2 necessarily HIV-infected) performed in 1994 at the same hospital as our study found a lower 3 carriage rate of CoT resistant pneumococci (13%) (52). Although one cannot exclude the 4 possibility that the difference is due to differences in methodology. Penicillin non-susceptibility 5 in S. pneumoniae was lower (14%) in 1994 compared with our data (27%). This emphasises the 6 pressing threat of antibiotic resistance. In contrast, tetracycline resistance levels of S. 7 pneumoniae were lower in this (11% at baseline) compared with previous studies (23%) (52). 8
This observation is consistent with a reduction of tetracycline prescriptions in children from 1996 9 (James CL Mwansa, personal communication). In agreement with other studies a low level of 10 resistance was observed to chloramphenicol (51). 11
The high levels of CoT resistant microorganisms carried in the nasopharynx while CoT 12
prophylaxis remains efficacious suggests that the relationship between carriage and invasive 13 organisms is not straightforward (7;21;38;52). Studies from other developing countries indicate 14 that most of the mortality among children is due to respiratory tract infections with S. 15 pneumoniae and thus, is likely to also be the case in this study (21;36). Some invasive 16 pneumococcal serotypes, for example serotype 1, are difficult to capture and probably carried for 17 short durations. This would limit their exposure to antibiotics and hence the acquisition of 18 resistance is reduced despite the relatively high rate of CoT resistance observed in other serotypes 19 that are frequently carried (46). Further studies are required to resolve this interesting paradox by 20 comparing invasive and carriage isolates at both the serotype and genotype level. in America showed that while there was no effect on pneumococcal carriage higher levels of 4 resistance to penicillin and CoT were observed (1). A more recent study in Zambia indicated that 5
CoT prophylaxis reduced colonization by about 7% and increased the risk of colonization with 6
CoT-resistant pneumococci within 6 weeks of starting prophylaxis (20). There is little data on the 7 effects of CoT prophylaxis on the nasopharyngeal carriage of H. influenzae. 8 CD4 level. The immune status of the host is also an important variable in the carriage and 9 therefore risk of invasive disease (14;16). S. pneumoniae is a frequent and serious infection in 10 HIV-1-infected adults in Africa (18;19), North America (47), and Europe (13). In our study on 11 HIV-infected children no association was found between CD4 levels and the carriage of both S. 
<0.001
*Changes in the probability of carriage over time estimated separately for placebo and CoT 1 treatment arms, without adjustment for any other factors. 2 **Estimated from fixed effects logistic regression as mixed models estimating the effect of CD4 3 % and CD4 % change from baseline on carriage of S. pneumoniae were unstable. 4 Table 2 . Odds ratios for nasopharyngeal carriage of S. pneumoniae and H. influenzae from 5 mixed effects logistic regression models with the child as a random effect. All odds ratios 6 are adjusted for time from randomisation and treatment arm.
Sequence of test results
Trial arm result. 4 ** Rate column normalises probabilities to total person-time at risk between tests which differs 5 between groups because of higher survival rates in CoT. 6 † Calculating using cause-specific hazards for subsequent test result being resistance vs 7 sensitive. Global test for difference between Placebo and CoT across all 4 sequences, p=0.29. 
